Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug Review Personnel Costs Dropping, Remain “Completely Normal,” FDA Says

Executive Summary

Decrease is part of a trend of increasing non-personnel expenses related to human drug review, which may indicate FDA cost containment, but also comes with another user fee increase.

You may also be interested in...



Thanks Sequester: FDA’s Human Drug Review Costs Decrease To Pre-FY 2011 Level

The agency says human drug review costs were less than $1 billion in fiscal year 2013, the first time that’s happened since FY 2010.

Obama’s FY 2015 Budget Is A Non-Starter, But Is It Still Bad For FDA?

Agency advocates may face stronger headwinds in their efforts to boost FDA funding after presidential budget request comes in nearly flat.

GDUFA: Fee Avoidance Affects Rates Again

Industry avoided application supplement fees by using CBE submissions instead, forcing FDA to change its estimates and sending generic drug user fees higher.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS055534

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel